Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...

She first had an episode of gross hematuria in her early 20’s. This was accompanied by flank pain, and she was given a course of empiric antibiotics. However, over the years, she has had multiple ...

Researchers evaluated the time to first major renal event in over 13,000 patients with type 2 diabetes and atherosclerotic cardiovascular disease.

A subgroup analysis of the PUSH trial sought to answer the research question: Does an incremental increase in urine volume provide benefit at different levels of baseline urine volume?

Individuals with diabetes are at an increased risk of developing dementia, according to a study published in the June issue of Diabetes, Obesity and Metabolis ...

The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has fired two key leaders of the task force that sets insurance coverage rules. Dr. John Wong, ...

Active repetitive transcranial magnetic stimulation also linked to lower societal costs, higher QALYs than sham.

Topline results from the phase 3 REDUCE 2 trial show that investigational pozdeutinurad effectively lowers serum uric acid in adults with gout.

Genitourinary adverse events seen in both groups; similarly, very low rates of gastrointestinal adverse events seen with 2F SBRT, 5F SBRT.